In July 2025, REPL announced it had received a CRL for its biologics license application (BLA) for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma patients who were PD-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results